Gilead Sciences Inc is a research-based biopharmaceutical company that provides medicines to prevent and treat life-threatening diseases including human immunodeficiency virus (HIV), viral hepatitis, and cancer. The company operates through one segment, which focuses on the discovery, development, and commercialization of medicines in areas with unmet medical needs. Gilead’s approved products for the treatment of HIV include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. It offers Veklury (remdesivir), an injection for intravenous administration for the treatment of coronavirus disease 2019 (COVID-19) in certain adults and children. The company’s approved products for liver diseases are Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Its products approved for hematology, oncology, and cell therapy consist of Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Trodelvy (sacituzumab govitecan-hziy), and Zydelig (idelalisib). The company’s research and development (R&D) efforts focus on viral diseases, inflammatory diseases, and cancer.
Livdelzi (Seladelpar) for the Treatment of Primary Biliary Cholangitis, USA
Livdelzi® (seladelpar) received accelerated approval from the US FDA in August 2024 for treating primary biliary cholangitis.
